The Cancer Genomics Laboratory is performing a comparative genomics study of transcription factors Foxa and estrogen receptor alpha between liver cancer and breast cancer. The goal is to provide in vivo evidence for cancer genomics to guide cancer therapeutic studies. The study will also address the mechanisms of tissue-specific genetic and epigenetic regulation of gene transcription (liver versus mammary gland).
The study is being conducted in mouse models and human tissues using genomic and proteomic approaches, such as next-generation sequencing (ChIP-sequencing) and mass spectrometry.
The Cancer Genomics Laboratory is also engaged in other research studies, including:
- Individualized medicine, including genomic studies of personalized diagnosis and therapeutics for human cancers
- Regenerative medicine, including genomic and epigenomic studies on the regulation of stem cell differentiation